Takeda In-Licenses Teva's Copaxone As Japan Orphan Drug
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceutical reached an agreement with Teva Pharmaceutical Industries to in-license, obtain approval and market Copaxone (glatiramer) for treating multiple sclerosis.